Cargando…
337 Targeting metabolic and epigenetic programs to re-sensitize glioblastoma to chemotherapy
OBJECTIVES/GOALS: Treatment options for glioblastoma (GBM) are limited. Prognosis remains dismal, with an 18 month on average survival rate following diagnosis due to treatment resistance and disease recurrence. The goal of this project is to investigate hallmarks of cancer progression that contribu...
Autores principales: | Rowland, Emma, Walter, Thomas, Suter, Robert, Jermakowicz, Anna, Riggins, Rebecca, Ayad, Nagi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10129721/ http://dx.doi.org/10.1017/cts.2023.382 |
Ejemplares similares
-
MDB-38. COMPUTATIONAL DRUG SENSITIVITY PREDICTS MEDULLOBLASTOMA SUBGROUP-SPECIFIC THERAPEUTICS
por: Jermakowicz, Anna, et al.
Publicado: (2023) -
BSCI-23 ANEUPLOIDY PROFILING IN GLIOBLASTOMA IDENTIFIES MECHANISMS OF DISEASE PROGRESSION AND TREATMENT VULNERABILITIES
por: Jermakowicz, Anna, et al.
Publicado: (2022) -
The novel BET inhibitor UM-002 reduces glioblastoma cell proliferation and invasion
por: Jermakowicz, Anna M., et al.
Publicado: (2021) -
Immunotherapy and Epigenetic Pathway Modulation in Glioblastoma Multiforme
por: Chin, Christopher, et al.
Publicado: (2018) -
317 Omics based analysis to identify novel markers of TMZ response in Glioblastoma Multiforme
por: Reed, Megan R., et al.
Publicado: (2023)